Equities Analysts Offer Predictions for TERN FY2030 Earnings

Terns Pharmaceuticals, Inc. (NASDAQ:TERN) – HC Wainwright issued their FY2030 EPS estimates for shares of Terns Pharmaceuticals in a report released on Wednesday, March 25th. HC Wainwright analyst A. Maldonado forecasts that the company will earn ($1.60) per share for the year. HC Wainwright currently has a “Neutral” rating and a $53.00 price objective on the stock. The consensus estimate for Terns Pharmaceuticals’ current full-year earnings is ($1.19) per share.

Several other research firms have also recently weighed in on TERN. UBS Group upgraded Terns Pharmaceuticals to a “strong-buy” rating in a report on Thursday, December 4th. TD Cowen reaffirmed a “hold” rating and set a $53.00 price objective on shares of Terns Pharmaceuticals in a report on Thursday. Leerink Partners started coverage on Terns Pharmaceuticals in a research report on Monday, February 9th. They set an “outperform” rating and a $58.00 target price for the company. Mizuho raised their target price on shares of Terns Pharmaceuticals from $33.00 to $54.00 and gave the company an “outperform” rating in a report on Tuesday, December 9th. Finally, BMO Capital Markets boosted their price target on shares of Terns Pharmaceuticals from $35.00 to $54.00 and gave the stock an “outperform” rating in a research report on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $56.90.

Terns Pharmaceuticals Trading Up 0.6%

Shares of TERN stock opened at $53.17 on Thursday. The stock has a market capitalization of $5.52 billion, a price-to-earnings ratio of -51.62 and a beta of -0.31. Terns Pharmaceuticals has a 12-month low of $1.87 and a 12-month high of $53.19. The stock’s 50-day moving average price is $40.96 and its 200-day moving average price is $28.74.

Insider Activity at Terns Pharmaceuticals

In other news, CEO Amy L. Burroughs sold 14,583 shares of the firm’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $46.71, for a total value of $681,171.93. Following the completion of the sale, the chief executive officer directly owned 288,976 shares of the company’s stock, valued at $13,498,068.96. This trade represents a 4.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Emil Kuriakose sold 1,155 shares of Terns Pharmaceuticals stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $38.57, for a total value of $44,548.35. Following the completion of the transaction, the insider owned 50,365 shares of the company’s stock, valued at approximately $1,942,578.05. This trade represents a 2.24% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 170,409 shares of company stock worth $6,563,769 over the last three months. 1.50% of the stock is currently owned by insiders.

Institutional Trading of Terns Pharmaceuticals

A number of institutional investors have recently bought and sold shares of TERN. Morgan Stanley increased its position in Terns Pharmaceuticals by 4.7% during the fourth quarter. Morgan Stanley now owns 7,945,608 shares of the company’s stock valued at $321,003,000 after acquiring an additional 356,513 shares during the last quarter. Commodore Capital LP bought a new stake in shares of Terns Pharmaceuticals in the 3rd quarter worth about $42,807,000. Adage Capital Partners GP L.L.C. lifted its holdings in shares of Terns Pharmaceuticals by 40.9% in the 4th quarter. Adage Capital Partners GP L.L.C. now owns 5,550,000 shares of the company’s stock worth $224,220,000 after acquiring an additional 1,611,000 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of Terns Pharmaceuticals by 21.1% during the 4th quarter. Vanguard Group Inc. now owns 5,523,948 shares of the company’s stock worth $223,167,000 after purchasing an additional 964,031 shares during the period. Finally, Vestal Point Capital LP bought a new position in Terns Pharmaceuticals during the 4th quarter valued at about $181,800,000. 98.26% of the stock is currently owned by institutional investors.

More Terns Pharmaceuticals News

Here are the key news stories impacting Terns Pharmaceuticals this week:

• Positive Sentiment: Merck agreed to buy Terns for $53.00 per share in cash, valuing the company at about $6.7 billion — investors view this as a strong exit valuation and strategic validation of Terns’ lead hematology asset, TERN‑701. Merck to Acquire Terns — Business Wire
• Positive Sentiment: Market reaction: shares traded with far above‑average volume and hit a new 52‑week high as the deal priced a near‑term valuation floor for shareholders. Terns Hits New 52‑Week High — American Banking News
• Neutral Sentiment: Deal mechanics and timing — Merck’s agreement is structured as a tender offer subject to customary conditions and shareholder participation; closing was guided for Q2 2026, so completion risk and timeline remain relevant. Merck Buyout Coverage — Reuters
• Neutral Sentiment: Analyst posture unchanged around the deal: several firms (HC Wainwright, TD Cowen, Citizens/JMP) reaffirmed neutral/hold ratings or price targets very close to the $53 offer price, implying limited upside beyond the bid while the transaction is pending. Analyst Notes & Ratings — MarketBeat
• Negative Sentiment: Litigation/investigations: multiple shareholder law firms have launched probes into whether the $53 per‑share price and sale process were fair — these challenges could delay closing, increase transaction costs, or pressure the timeline. Investor Alert — Kahn Swick & Foti (Business Wire)

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.